DermTech, Inc. – NASDAQ:DMTK
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
DermTech stock price monthly change
-75.90%
month
DermTech stock price quarterly change
-92.71%
quarter
DermTech stock price yearly change
-96.40%
year
DermTech key metrics
Market Cap | 3.28M |
Enterprise value | 108.74M |
P/E | -1.12 |
EV/Sales | 7.49 |
EV/EBITDA | -0.98 |
Price/Sales | 9.00 |
Price/Book | 0.98 |
PEG ratio | 0.02 |
EPS | -2.7 |
Revenue | 15.66M |
EBITDA | -85.33M |
Income | -89.62M |
Revenue Q/Q | 10.58% |
Revenue Y/Y | 9.71% |
Profit margin | -803.71% |
Oper. margin | -813.92% |
Gross margin | 4.46% |
EBIT margin | -813.92% |
EBITDA margin | -544.78% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDermTech stock price history
DermTech stock forecast
DermTech financial statements
| Jun 2023 | 3.98M | -31.36M | -788.02% |
|---|---|---|---|
| Sep 2023 | 3.91M | -19.16M | -489.5% |
| Dec 2023 | 3.92M | -19.09M | -486.52% |
| Mar 2024 | 3.84M | -20.01M | -520.42% |
| Sep 2025 | 5.37M | -14.76M | -274.86% |
|---|---|---|---|
| Oct 2025 | 4.48M | -18.04M | -402.7% |
| Dec 2025 | 5.93M | -12.51M | -211.11% |
| Dec 2025 | 4.44M | -17.70M | -398.16% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 157074000 | 68.99M | 43.93% |
|---|---|---|---|
| Sep 2023 | 137896000 | 64.83M | 47.02% |
| Dec 2023 | 121930000 | 64.75M | 53.11% |
| Mar 2024 | 102970000 | 62.97M | 61.16% |
| Jun 2023 | -23.20M | 13.05M | 4.46M |
|---|---|---|---|
| Sep 2023 | -19.04M | 12.75M | 726K |
| Dec 2023 | -12.70M | 12.24M | -24K |
| Mar 2024 | -17.11M | 7.83M | 122K |
DermTech alternative data
DermTech Social Media Accounts
What are followers?
-0.29%
month
| May 2025 | 10580 |
|---|---|
| Jul 2025 | 10541 |
| Aug 2025 | 10510 |
DermTech
| 26 Feb 2023 | 4 |
|---|---|
| 5 Mar 2023 | 6 |
| 12 Mar 2023 | 0 |
| 19 Mar 2023 | 2 |
| 26 Mar 2023 | 0 |
| 2 Apr 2023 | 8 |
| 9 Apr 2023 | 16 |
| 16 Apr 2023 | 6 |
| 23 Apr 2023 | 15 |
| 30 Apr 2023 | 9 |
| 7 May 2023 | 5 |
| 14 May 2023 | 5 |
| 21 May 2023 | 9 |
| 28 May 2023 | 12 |
| 4 Jun 2023 | 8 |
| 11 Jun 2023 | 0 |
| 18 Jun 2023 | 0 |
| 25 Jun 2023 | 3 |
| 2 Jul 2023 | 10 |
| 9 Jul 2023 | 22 |
Melanoma Detection
| 12 Feb 2023 | 0 |
|---|---|
| 19 Feb 2023 | 0 |
| 26 Feb 2023 | 0 |
| 5 Mar 2023 | 40 |
| 12 Mar 2023 | 46 |
| 19 Mar 2023 | 53 |
| 26 Mar 2023 | 0 |
| 2 Apr 2023 | 25 |
| 9 Apr 2023 | 26 |
| 16 Apr 2023 | 57 |
| 23 Apr 2023 | 0 |
| 30 Apr 2023 | 24 |
| 7 May 2023 | 0 |
| 14 May 2023 | 19 |
| 21 May 2023 | 52 |
| 28 May 2023 | 22 |
| 4 Jun 2023 | 20 |
| 11 Jun 2023 | 0 |
| 18 Jun 2023 | 0 |
| 25 Jun 2023 | 17 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 11 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 18 |
| Nov 2023 | 9 |
| Dec 2023 | 6 |
| Jan 2024 | 9 |
| Feb 2024 | 3 |
| Apr 2024 | 0 |
| May 2024 | 0 |
| Jun 2024 | 0 |
| Jul 2024 | 0 |
| Dec 2024 | 0 |
| Aug 2023 | 278 |
|---|---|
| Sep 2023 | 278 |
| Oct 2023 | 278 |
| Nov 2023 | 278 |
| Dec 2023 | 278 |
| Jan 2024 | 278 |
| Feb 2024 | 278 |
| Mar 2024 | 206 |
| Apr 2024 | 206 |
| May 2024 | 206 |
| Jun 2024 | 206 |
| Jul 2024 | 206 |
DermTech other data
21.24%
-6.58%
of DMTK is owned by hedge funds
69
-19
6.37M
-1.99M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 0 | 65164 |
| Jun 2023 | 0 | 23980 |
| Sep 2023 | 0 | 21847 |
| Dec 2023 | 0 | 16043 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SUN KEVIN M officer: Chief Financial Officer | Common Stock | 447 | $1.45 | $648 | ||
Sale | IBARRA CLAUDIA officer: Chief Op.. | Common Stock | 331 | $1.45 | $480 | ||
Sale | IBARRA CLAUDIA officer: Chief Op.. | Common Stock | 2,607 | $1.41 | $3,676 | ||
Sale | SUN KEVIN M officer: Chief Financial Officer | Common Stock | 188 | $1.53 | $288 | ||
Sale | SUN KEVIN M officer: Chief Financial Officer | Common Stock | 2,248 | $1.53 | $3,439 | ||
Sale | SUN KEVIN M officer: Chief Financial Officer | Common Stock | 2,543 | $1.53 | $3,891 | ||
Sale | IBARRA CLAUDIA officer: Chief Op.. | Common Stock | 143 | $1.53 | $219 | ||
Sale | IBARRA CLAUDIA officer: Chief Op.. | Common Stock | 1,768 | $1.53 | $2,705 | ||
Sale | IBARRA CLAUDIA officer: Chief Op.. | Common Stock | 2,000 | $1.53 | $3,060 | ||
Sale | AKHAVAN RAMIN officer: General Counsel | Common Stock | 1,768 | $1.53 | $2,705 |
| Patent |
|---|
Application Filling date: 23 Nov 2021 Issue date: 26 May 2022 |
Grant Filling date: 25 Jul 2019 Issue date: 17 May 2022 |
Application Filling date: 7 May 2021 Issue date: 11 Nov 2021 |
Application Filling date: 22 Jun 2021 Issue date: 28 Oct 2021 |
Application Filling date: 21 Apr 2021 Issue date: 28 Oct 2021 |
Application Filling date: 22 Jun 2021 Issue date: 21 Oct 2021 |
Application Filling date: 30 Mar 2021 Issue date: 12 Aug 2021 |
Application Filling date: 30 Mar 2021 Issue date: 22 Jul 2021 |
Application Filling date: 26 Mar 2021 Issue date: 22 Jul 2021 |
Application Filling date: 26 Mar 2021 Issue date: 22 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 4 May 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. John D. Dobak (1966) Pres, Chief Executive Officer & Director | $667,760 |
Mr. Kevin Sun M.B.A. (1978) Chief Financial Officer, Treasurer & Sec. | $378,150 |
| Ms. Claudia Ibarra (1962) Chief Operating Officer | $350,390 |
Immunocore: Potential To Unlock Capital With New Melanoma Treatment Paradigm
Diving Into DermTech
DermTech: Approaching An All Or Nothing Moment
Fed Tomfoolery: 5 Top Stocks - 3 Pure-Growth, 2 Dividend-Growth
DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics
DermTech: Transforming The Melanoma Diagnosis Landscape
DermTech: Becoming More Appealing, Despite Nosebleed Valuation
DermTech: Revolutionizing The Skin Cancer Diagnostics Market
DermTech: Disrupting Skin Cancer Testing
-
When is DermTech's next earnings date?
Unfortunately, DermTech's (DMTK) next earnings date is currently unknown.
-
Does DermTech pay dividends?
No, DermTech does not pay dividends.
-
How much money does DermTech make?
DermTech has a market capitalization of 3.28M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.36% to 15.3M US dollars.
-
What is DermTech's stock symbol?
DermTech, Inc. is traded on the NASDAQ under the ticker symbol "DMTK".
-
What is DermTech's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of DermTech?
Shares of DermTech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are DermTech's key executives?
DermTech's management team includes the following people:
- Dr. John D. Dobak Pres, Chief Executive Officer & Director(age: 59, pay: $667,760)
- Mr. Kevin Sun M.B.A. Chief Financial Officer, Treasurer & Sec.(age: 47, pay: $378,150)
- Ms. Claudia Ibarra Chief Operating Officer(age: 63, pay: $350,390)
-
How many employees does DermTech have?
As Jul 2024, DermTech employs 206 workers.
-
When DermTech went public?
DermTech, Inc. is publicly traded company for more then 8 years since IPO on 10 Aug 2017.
-
What is DermTech's official website?
The official website for DermTech is dermtech.com.
-
Where are DermTech's headquarters?
DermTech is headquartered at 11099 North Torrey Pines Road, La Jolla, CA.
-
How can i contact DermTech?
DermTech's mailing address is 11099 North Torrey Pines Road, La Jolla, CA and company can be reached via phone at 858 450 4222.
DermTech company profile:
DermTech, Inc.
dermtech.comExchange:
NASDAQ
Full time employees:
206
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
11099 North Torrey Pines Road
La Jolla, CA 92037
La Jolla, CA 92037
CIK: 0001651944
ISIN: US24984K1051
CUSIP: 24984K105
